search
Back to results

Mitochondrial Stress, Brain Imaging, and Epigenetics (MiSBIE)

Primary Purpose

Mitochondrial Diseases

Status
Suspended
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Trier social stress test
Sponsored by
Columbia University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Mitochondrial Diseases focused on measuring Mitochondria, Brain Imaging, Psychophysiology, Epigenetics, Stress, Metabolic rate, Mitochondrial function

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Men and women patients between 18 and 55 years of age
  • Willing to provide saliva samples and have venous catheter installed for blood collection during the hospital visit
  • Willing to provide informed consent and capacity to consent
  • Use of effective method of birth control for women of childbearing capacity
  • English Speaking

Exclusion Criteria:

  • Individuals with cognitive deficit incapable of providing informed consent will not be included
  • Symptoms of flu or other seasonal infection four weeks preceding hospital visit
  • Raynaud's syndrome (Raynaud phenomenon)
  • Involvement in any therapeutic trials listed on clinicaltrials.gov, including exercise
  • Metal inside or outside the body or claustrophobia prohibitive to MRI testing
  • Diagnosed with mitochondrial disease m.3243A>G, or large scale mtDNA deletion (for healthy controls)

Sites / Locations

  • Columbia University Irving Medical Center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

Healthy controls

Mutation

Mutation with MELAS

Deletion

Arm Description

No diagnosis of mitochondrial disease

Participants carrying the m.3243A>G point mutation, without a diagnosis of MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes)

Participants carrying the m.3243A>G point mutation, with a diagnosis of MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes)

Participants carrying a single, large-scale mtDNA deletion

Outcomes

Primary Outcome Measures

Average TSST-induced elevation in cortisol
This is designed to measure cortisol reactivity to the trier social stress test (TSST), quantified from salivary cortisol (LC-MS) over an 8-timepoints timecourse. The elevation will be measured as the area under the curve (AUC) for the cortisol time course.
Average allostatic load index
Groups will be compared on a quantitative allostatic load (AL) index integrating baseline fasting measures of neuroendocrine, immune and metabolic systems, urinary catecholamines, hematological measures, and hair/diurnal cortisol levels.

Secondary Outcome Measures

Average TSST-induced elevation in heart rate
Groups will be compared on heart rate (HR) as a measure of cardiovascular reactivity to stress, monitored using a continuous 3-lead ECG. The elevation will be computed from the baseline HR to the peak HR reached during the TSST.
Correlation between anxiety and mitochondrial respiration
The association between mitochondrial respiration using extracellular flux analysis (Seahorse) on blood lymphocytes, and anxiety symptoms measured using the state and trait anxiety inventory (STAI), will be quantified by a linear regression across all study participants.
Average neuropsychological function
Groups will be compared on the fluency/initiation domain of executive functioning assessed using the Delis-Kaplan Executive Function System (D-KEFS) test.

Full Information

First Posted
March 31, 2021
Last Updated
August 22, 2023
Sponsor
Columbia University
Collaborators
Dartmouth College, Centre National de la Recherche Scientifique, France, Massachusetts General Hospital, Technische Universität Dresden, National Institute of Mental Health (NIMH)
search

1. Study Identification

Unique Protocol Identification Number
NCT04831424
Brief Title
Mitochondrial Stress, Brain Imaging, and Epigenetics
Acronym
MiSBIE
Official Title
The Mitochondrial Stress, Brain Imaging, and Epigenetics Study
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Suspended
Why Stopped
The study is on pause.
Study Start Date
June 12, 2018 (Actual)
Primary Completion Date
December 2024 (Anticipated)
Study Completion Date
April 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Columbia University
Collaborators
Dartmouth College, Centre National de la Recherche Scientifique, France, Massachusetts General Hospital, Technische Universität Dresden, National Institute of Mental Health (NIMH)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The MiSBIE study collects biological, behavioral, psychosocial, neuropsychological, and brain imaging data in participants with either: normal mitochondrial function, individuals with the m.3243A>G mitochondrial DNA (mtDNA) mutation, and individuals a single large-scale mtDNA deletion. These defects induce mitochondrial allostatic load (MAL). The 2-day protocol, plus home-based data collection, will provide a comprehensive assessment of the multi-systemic dysregulation associated with MAL or mitochondrial dysfunction, and the link to physical and mental health-related symptoms. Aim 1: Determine the influence of MAL on systemic AL biomarkers. Aim 2: Establish the influence of MAL on stress reactivity profiles. Aim 3. Examine the association between MAL and psychological functioning.
Detailed Description
Age-related physical and cognitive decline, as well as the risk of neurological diseases, are increased by the effects of psychosocial stress. Psychosocial stress triggers neuroendocrine, metabolic, cardiovascular, and inflammatory changes in the body. These changes vary in nature and magnitude between individuals, and are associated with long-term disease risk. However, the biological determinants of the stress response are not well understood. This project aims to translate the preclinical findings (how mitochondria regulate the different organ systems and major stress response axes are activated during psychological stress) by studying a population of individuals with varying degree of mitochondrial dysfunction, and to test potential neural mechanism, and why some individuals respond more strongly than others to the same stressor. Each participant will be studied over two consecutive days. Participants will be housed on campus to standardize study conditions. On Day 1, participants will donate blood and saliva, undergo a neuropsychological assessment, and complete questionnaires to assess psychosocial functioning and psychiatric symptoms. After lunch, the investigator will monitor dynamic changes in mental health-related biological outcomes (positive and negative affect, circulating levels of the inflammatory cytokine IL-6, and salivary cortisol) in response to a standardized laboratory challenge. On Day 2, participants will undergo a medical evaluation to assess clinical symptoms and undergo a whole brain neuroimaging session where both resting and stress elicited activity will be measured. A variant of the same stressor as on Day 1 will be used in the neuroimaging session. Participants will then be debriefed, concluding the individuals participation in the study. Participants also complete a home-based saliva and stool collection to examine diurnal variation in salivary hormones, and to examine microbiome composition. This translational project will generate a unique combination of complimentary molecular, cellular, and neuroimaging data that will advance our understanding of the links between mitochondria, the brain, and mental health-related outcomes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mitochondrial Diseases
Keywords
Mitochondria, Brain Imaging, Psychophysiology, Epigenetics, Stress, Metabolic rate, Mitochondrial function

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
All participants will undergo TSST and have samples With DNA collected (blood plasma and serum, purified leukocytes, saliva, urine, buccal epithelial cells, hair are stored).
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Healthy controls
Arm Type
Experimental
Arm Description
No diagnosis of mitochondrial disease
Arm Title
Mutation
Arm Type
Experimental
Arm Description
Participants carrying the m.3243A>G point mutation, without a diagnosis of MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes)
Arm Title
Mutation with MELAS
Arm Type
Experimental
Arm Description
Participants carrying the m.3243A>G point mutation, with a diagnosis of MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes)
Arm Title
Deletion
Arm Type
Experimental
Arm Description
Participants carrying a single, large-scale mtDNA deletion
Intervention Type
Behavioral
Intervention Name(s)
Trier social stress test
Other Intervention Name(s)
TSST
Intervention Description
The Trier social stress test (TSST) is a tool for investigating psychobiological stress responses in a laboratory setting. It is a laboratory procedure used to reliably induce stress in human research participants. The study is not examining or validating the test itself but rather using it as a tool to measure the response/focus of study.
Primary Outcome Measure Information:
Title
Average TSST-induced elevation in cortisol
Description
This is designed to measure cortisol reactivity to the trier social stress test (TSST), quantified from salivary cortisol (LC-MS) over an 8-timepoints timecourse. The elevation will be measured as the area under the curve (AUC) for the cortisol time course.
Time Frame
Day 1 post challenge (approximately 2 hours)
Title
Average allostatic load index
Description
Groups will be compared on a quantitative allostatic load (AL) index integrating baseline fasting measures of neuroendocrine, immune and metabolic systems, urinary catecholamines, hematological measures, and hair/diurnal cortisol levels.
Time Frame
Blood collected on Day 1
Secondary Outcome Measure Information:
Title
Average TSST-induced elevation in heart rate
Description
Groups will be compared on heart rate (HR) as a measure of cardiovascular reactivity to stress, monitored using a continuous 3-lead ECG. The elevation will be computed from the baseline HR to the peak HR reached during the TSST.
Time Frame
Day 1 post challenge (approximately 2 hours)
Title
Correlation between anxiety and mitochondrial respiration
Description
The association between mitochondrial respiration using extracellular flux analysis (Seahorse) on blood lymphocytes, and anxiety symptoms measured using the state and trait anxiety inventory (STAI), will be quantified by a linear regression across all study participants.
Time Frame
Day 1
Title
Average neuropsychological function
Description
Groups will be compared on the fluency/initiation domain of executive functioning assessed using the Delis-Kaplan Executive Function System (D-KEFS) test.
Time Frame
Day 2 neuropsychological session

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Men and women patients between 18 and 55 years of age Willing to provide saliva samples and have venous catheter installed for blood collection during the hospital visit Willing to provide informed consent and capacity to consent Use of effective method of birth control for women of childbearing capacity English Speaking Exclusion Criteria: Individuals with cognitive deficit incapable of providing informed consent will not be included Symptoms of flu or other seasonal infection four weeks preceding hospital visit Raynaud's syndrome (Raynaud phenomenon) Involvement in any therapeutic trials listed on clinicaltrials.gov, including exercise Metal inside or outside the body or claustrophobia prohibitive to MRI testing Diagnosed with mitochondrial disease m.3243A>G, or large scale mtDNA deletion (for healthy controls)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Martin Picard, PhD
Organizational Affiliation
Columbia University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Columbia University Irving Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
All data will be deposited to the NIMH Data Archive.
IPD Sharing Time Frame
Data will be made available at the end of the study, without a expiry date.
IPD Sharing Access Criteria
Access will be handled through the NIMH Data Archive (NDA)
IPD Sharing URL
https://nda.nih.gov
Links:
URL
http://www.picardlab.org/uploads/7/7/8/4/77845210/1_misbie_brochure_2018-06-26.pdf
Description
Study Brochure

Learn more about this trial

Mitochondrial Stress, Brain Imaging, and Epigenetics

We'll reach out to this number within 24 hrs